Japan Flu Diagnostic And Treatment Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), And By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory) - Forecasts From 2022 To 2027

The Japanese flu diagnostic and treatment market is projected to grow at a CAGR of 13.72% throughout the forecast period and reach a market size of US$6,370.697 million by 2027. The market was valued at US$2,590.835 million in 2020.

The low Vaccination rate and rising prevalence of influenza are expected to drive the market growth

The flu diagnostic and treatment market in Japan is growing due to the low vaccination rate among people and the ineffectiveness of vaccination. The rising prevalence of influenza across Japan is a driving factor for the flu diagnostic and treatment market. In 2018, an estimated 1.24 million people, mainly in southwestern and western Japan, had the flu in the first week of January, according to the National Institute of Infectious Diseases. In 2019, Japan had a serious influenza outbreak in the week-January 21-27, with more than 2 million people who underwent medical consultations in Japan for influenza during that week. These outbreaks in the country are increasing the demand for flu diagnostics and treatment.

The growing geriatric population in Japan is a major driving factor for the flu diagnostic and treatment market.

 The continuously rising geriatric population in Japan due to better health facilities and improved lifestyles has increased the average life expectancy. Their health is improving because of the increasing awareness about their health and the incorporation of healthy eating habits and exercise into their lives. The growing economy of Japan has increased disposable income which has further helped people improve their health by going to the gym, eating healthy food, taking medicine as prescribed by the doctor, and doing exercise and yoga to keep themselves fit.

This change in the lifestyles of people with better facilities has increased the average age of the population. This is increasing the demand for flu diagnosis and treatment in the country as the aged population is more susceptible to catching the flu. According to the World Bank, the population of people 65 and above in 2008 was 27,195,327, which rose to 34,892,133 in 2018 in Japan. The rising geriatric population of Japan is expected to be a major boosting factor for the flu diagnostic and treatment market in the country.

Increased government initiatives and advancements in technology

Increasing government initiatives and advancements in technology will further grow the market. Japan is known to be one of the most advanced countries in terms of technology. This will help them in improvising their research and development in producing better quality vaccines for a stronger and healthier nation

Japan’s flu diagnostic and treatment market has been segmented based on the type of flu, offering, age group, and end-user. The market has been classified based on type A and type B based on the type of flu. By offering, the market has been segmented into diagnostics and therapeutics. By age group, the market has been segmented based on 0-14 years, 15-64 years, and >=65 years. By the end-user, the segmentation has been done based on the hospital laboratory, outpatient clinic, and reference laboratory.

Key Developments

• April 2020: Japan-based FUJIFILM announced the expansion of its production capacity of Avigan, an antiviral influenza drug, to use the drug in the treatment of COVID. At its Wako Pure Chemical Co., Ltd. facility in the country, Fujifilm allocated extra capacity for the manufacturing of pharmaceutical intermediates used in the manufacture of Avigan to increase the supply of the drug further. In order to procure raw materials and pharmaceutical ingredients for its various production processes, Fujifilm has also formed strategic alliances with domestic and international businesses. With this development, the firm aimed to increase its monthly production quota by 2.5 times compared to its production in March to 100,000 by July of that year, as mentioned on the company’s website.
• February 2022: GSK Pharma, which is also active in Japan, stated its intention to upscale the production of vaccines, GSK's one of the largest growth factors, from 2021 through 2026 in its annual report 2021. In this period, the firm aims to upscale the production of the flu vaccine by 2x, along with Shingles and meningitis vaccines. 

COVID-19 Insights:

COVID-19 had a positive impact on the Japanese flu diagnostic and treatment market. Amid the growing prevalence of seasonal flu cases amid the pandemic, the consumption of flu and COVID-19 diagnostic kits increased to detect and diagnose the optimal treatment plan for the patient. At the same time, a few antiviral drugs deemed to have an effect on the SARS-CoV-2 were repurposed for the treatment. The production of such drugs increased in the country. The strategic initiative taken by Japan's Fujifilm to upscale the production of Avigan is the best example of this. Similar strategic developments had a positive impact on Japan's market in the aforementioned period.

Segmentation

• By Type of Flu
  • Type A
  • Type B
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • Others
  • Therapeutics
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By End-User
  • Hospital Laboratory
  • Outpatient Clinic
  • Reference Laboratory

---